Product Name :
Fatostatin hydrobromide
Description:
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
CAS:
298197-04-3
Molecular Weight:
375.33
Formula:
C18H19BrN2S
Chemical Name:
4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine; bromohydrogen
Smiles :
Br.CC1C=CC(=CC=1)C1=CSC(=N1)C1=CC(CCC)=NC=C1
InChiKey:
RJCFNQZVFUMORB-UHFFFAOYSA-N
InChi :
InChI=1S/C18H18N2S.BrH/c1-3-4-16-11-15(9-10-19-16)18-20-17(12-21-18)14-7-5-13(2)6-8-14;/h5-12H,3-4H2,1-2H3;1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Cryptotanshinone} medchemexpress|{Cryptotanshinone} JAK/STAT Signaling|{Cryptotanshinone} Protocol|{Cryptotanshinone} In Vitro|{Cryptotanshinone} supplier|{Cryptotanshinone} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.|Product information|CAS Number: 298197-04-3|Molecular Weight: 375.33|Formula: C18H19BrN2S|Chemical Name: 4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine; bromohydrogen|Smiles: Br.CC1C=CC(=CC=1)C1=CSC(=N1)C1=CC(CCC)=NC=C1|InChiKey: RJCFNQZVFUMORB-UHFFFAOYSA-N|InChi: InChI=1S/C18H18N2S.{{Doxorubicin} MedChemExpress|{Doxorubicin} Antibiotic|{Doxorubicin} Purity & Documentation|{Doxorubicin} In stock|{Doxorubicin} custom synthesis|{Doxorubicin} Autophagy} BrH/c1-3-4-16-11-15(9-10-19-16)18-20-17(12-21-18)14-7-5-13(2)6-8-14;/h5-12H,3-4H2,1-2H3;1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 22.PMID:24455443 73 mg/mL (60.56 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells.|In Vivo:|Fatostatin hydrobromide (125B11 hydrobromide) (30 mg/kg; 150 mL; i.p.; daily for 28 days) reduces adiposity, ameliorates fatty liver by reducing triglyceride (TG) storage, and lowers hyperglycemia in ob/ob mice.|Products are for research use only. Not for human use.|
